Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 66 Publications

13 Customer Reviews

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NWnOS5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnXeG9QPzJiaB?= NVXmd25ZTE2VTx?= MX3JR|UxRTBwMECwNFch|ryP NYmyXphCOTd7NU[wPFA>
K562 NX\kdW42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvSVFU{PzJiaB?= MYPEUXNQ MlHJTWM2OD1yLkCwNUDPxE1? M1j5TlE4QTV4MEiw
M07e M2LNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHJc5Y4OiCq MnTuSG1UVw>? MnnVTWM2OD1yLkCwNVIh|ryP NU\xUIVYOTd7NU[wPFA>
ALL3 MVzDfZRwfG:6aXOgRZN{[Xl? NXrF[|ViOC5zzszN MoLQO|IhcA>? MkP0SG1UVw>? M1TvS2lEPTB;MD6wNFA1KM7:TR?= NXTHcoRXOTl6OEm1OFA>
CML NXrIV5RtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TZXFIxKG2rbh?= NUe1[JRSTE2VTx?= MmjjTWM2OD1yLkCwNUDPxE1? NUHqXJp4OTl{MUmwNVY>
BA/F3 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jvfFczKGh? NGLsc|hFVVOR Mme4TWM2OD14LkW4PUDPxE1? MXiyN|A5QDZ2NB?=
BA/F3 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVG3NkBp NV3rNHoyTE2VTx?= MX3JcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?= MnfmNlMxQDh4NES=
BA/F3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jxeFczKGh? MYHEUXNQ MVXJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO MWeyN|A5QDZ2NB?=
BA/F3 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf5dI1uPzJiaB?= M3\zW2ROW09? M2LZSmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygWFMyPUlibYX0ZY51KHerdHigTWM2OCCxZjCxMlcyPM7:TR?= MVOyN|A5QDZ2NB?=
BA/F3 NVWzfVl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTCO|IhcA>? NFj1Xm5FVVOR MY\JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBHPDh4UzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECwPe69VQ>? NG\ROG8zOzNyMUewNy=>
BA/F3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;NPXVMPzJiaB?= MmfrSG1UVw>? M3KyZmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP MoDoNlM{ODF5MEO=
BA/F3 NFrySlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[3NkBp M37qTGROW09? MXLJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>? NFnwcXQzOzNyMUewNy=>
BA/F3 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXEO|IhcA>? M2fweWROW09? NV35ZY4xUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= NWP0fmdkOjN|MEG3NFM>
BA/F3 M{jhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPCdXFwPzJiaB?= NEjFO3JFVVOR NHruSGhKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= NIfvfHUzOzNyMUewNy=>
BA/F3 M37acGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rZNlczKGh? M4DTO2ROW09? M{W5fmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO NHeyTWgzOzNyMUewNy=>
BA/F3 M17BNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\BV4JmPzJiaB?= NVT6bXdkTE2VTx?= M4\uZmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFl{NUPIJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFI{|ryP MXqyN|MxOTdyMx?=
BA/F3 NV3CbIlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vieVczKGh? Mn25SG1UVw>? NVrXTG83UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiVEOxOWkhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCzMlbPxE1? MYKyN|MxOTdyMx?=
BA/F3 NV3McZpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\SV3VMPzJiaB?= NUDaTI17TE2VTx?= MmfYTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NHe5cHAzOzNyMUewNy=>
T cell M3HQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2K1[FczKGh? MVvEUXNQ Mnu5TY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0> MkXFNVcyPTR3MUK=
WiDr MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkn2O|IhcA>? M{DUTWROW09? MnPyTWM2OD1yLkC1NkDPxE1? MkXYNVU3OTV3MUK=
PC3 MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYC3NkBp NUXQfIRTTE2VTx?= MUHJR|UxRTBwMEC5OEDPxE1? MkjqNVU3OTV3MUK=
MDA-MB-231 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uwe|czKGh? MULEUXNQ NWfIPZBNUUN3ME2wMlAyOiEQvF2= M33GUFE2PjF3NUGy
Hs578T NXHITWNrS3m2b4TvfIlkKEG|c3H5 NUTTdYV2PzJiaB?= NGP4e29FVVOR MVXHTVUxRTBwMEOg{txO NWfQW4drOjRyMUWzNlc>
HMEC MX\DfZRwfG:6aXOgRZN{[Xl? MlfNO|IhcA>? M4niO2ROW09? M1rnc2dKPTB;MT64JO69VQ>? NYCwXnpzOjRyMUWzNlc>
DU145 MVTDfZRwfG:6aXOgRZN{[Xl? MV63NkBp MX3EUXNQ MVLHTVUxRTBwMU[g{txO MoXHNlQxOTV|Mke=
U251 NFPMSY1EgXSxdH;4bYMhSXO|YYm= MlHzO|IhcA>? NFPOdYhFVVOR NH36TmdIUTVyPUKuPFEh|ryP M2ewOlI1ODF3M{K3
NCI60 MWXDfZRwfG:6aXOgRZN{[Xl? M3PCR|czKGh? NEWxN2ZFVVOR M4niS2dKPTB;NT63JO69VQ>? M3uyWFI1ODF3M{K3
MALME-3M MV7DfZRwfG:6aXOgRZN{[Xl? MVu3NkBp M3rJc2ROW09? NHviVXBIUTVyPU[uOlEh|ryP NUfjfGRKOjRyMUWzNlc>
KM12 NGrUPGxEgXSxdH;4bYMhSXO|YYm= NW\nSYRWPzJiaB?= NES2e2xFVVOR NV;sfJY1T0l3ME23MlQ1KM7:TR?= MYmyOFAyPTN{Nx?=
SW620 MY\DfZRwfG:6aXOgRZN{[Xl? MniyO|IhcA>? MoHwSG1UVw>? M13GVmdKPTB;OD60N{DPxE1? MYGyOFAyPTN{Nx?=
RXF 393NL MXnDfZRwfG:6aXOgRZN{[Xl? Mne0OEBl[Xm| NHH6[FNFVVOR M13DWGlEPTB;MD6wNlE4KM7:TR?= M{nCcVI{OjV|MEe0
LXFA 983L M1H6OGN6fG:2b4jpZ{BCe3OjeR?= M3jtOFQh\GG7cx?= NFPEWFBFVVOR MnjoTWM2OD1yLkC1OlUh|ryP NHPkU2QzOzJ3M{C3OC=>
PRXF DU145 MV7DfZRwfG:6aXOgRZN{[Xl? MVm0JIRigXN? NH[2eWpFVVOR NGfuVllKSzVyPUCuNFYzOyEQvF2= MX[yN|I2OzB5NB?=
PAXF 1657L Mnf4R5l1d3SxeHnjJGF{e2G7 NEDUXpc1KGSjeYO= MnGwSG1UVw>? MVXJR|UxRTBwMUKxJO69VQ>? M3j2TFI{OjV|MEe0
CXF 1103L NVTMS4xsS3m2b4TvfIlkKEG|c3H5 MlTCOEBl[Xm| MY\EUXNQ NGrM[oNKSzVyPUSuN|Yh|ryP MUSyN|I2OzB5NB?=
GXF251L NEDrWmlEgXSxdH;4bYMhSXO|YYm= Ml\3OEBl[Xm| MkL3SG1UVw>? MUHJR|UxRTJwMkWg{txO Mm\mNlMzPTNyN{S=
NCI-H23 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4judlczKGh? NFfKN45FVVOR Mo\6TWM2OD1{LkK3JO69VQ>? M3LPSFI{PTJzMEKw
HCT116 NHXTSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPCO|IhcA>? M1GyVmROW09? M3;QbmlEPTB;Mj6zJO69VQ>? MXWyN|UzOTB{MB?=
MCF7 M2nNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfOO|IhcA>? Mk\HSG1UVw>? NYLlPI9QUUN3ME2yMlU4KM7:TR?= NULofog5OjN3MkGwNlA>
NCI-H460 NGHkUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;lNlczKGh? NFq1cGRFVVOR MmP2TWM2OD16Lkm5JO69VQ>? NWD1NY1tOjN3MkGwNlA>
DLD1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYe3NkBp M2HQZ2ROW09? M2TnNmlEPTB;ND62JO69VQ>? MlO2NlM2Pjd7NkC=
NCI-H661 NHLxXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rM[lczKGh? MVzEUXNQ M32wRmlEPTB;Nz64JO69VQ>? MUGyN|U3Pzl4MB?=
A549 M3PZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIexcXk4OiCq NVWwWYZCTE2VTx?= NWXaXJc3UUN3ME24MlIh|ryP NEfLfWEzOzV4N{m2NC=>
U937 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHFOWxpPzJiaB?= MkLBSG1UVw>? MmLHTWM2OD1zMj6yJO69VQ>? MkDpNlM2Pjd7NkC=
HEK293 M1\rbWZ2dmO2aX;uJGF{e2G7 MVOxNOKh|ryP MmjvSG1UVw>? MXXJcoR2[2W|IHLpcoRqdmdiYX\mbY5qfHlidH:gbJVu[W5iZoXscE1t\W6pdHigTIl{NXSjZ3fl[EBOgXRzIHvpcoF{\SCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHerdHigTWM2OCCxZjCwMlA3O87:TR?= MVSyNlc4ODZzMB?=
HUVEC M3;wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvYXVI6OC5zNdMg{txO MljZO|IhcA>? NWDMUWJITE2VTx?= NFTPOVRKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> NW\XS|FLOjJ6NUO5PVM>
HUVEC NYTVTWVPTnWwY4Tpc44hSXO|YYm= MXGxOeKh|ryP NInVcWk4OiCq MkTISG1UVw>? NI[3cI1KdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIH7leJdwemtiZn;ycYF1cW:wIHH0JFEvQCC2bzCxOUB2VQ>? M4HVflIzQDV|OUmz
Plasmodium falciparum M4HucmZ2dmO2aX;uJGF{e2G7 M4T0NFExyqEQvF2= NFv0ZWkyPSCvaX6= NUnZVoJ5TE2VTx?= MlvSTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO NITKfJkzPDV3MEOzNC=>
PC3 MWTGeY5kfGmxbjDBd5NigQ>? M3frT|AvOSEQvF2= M4TSSlUhcA>? NHXEPVBFVVOR NVLTRo1NUW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N M33qS|E6PDZ{OUe1
DU145 M1zFT2Z2dmO2aX;uJGF{e2G7 NYjWdWFPOC5zIN88US=> MkfROUBp MYnEUXNQ MnLxTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= NHnOXW4yQTR4Mkm3OS=>
PC3 MX\LbY5ie2ViQYPzZZk> NUW0UlZOOC5zIN88US=> M4P5OFUhcA>? NI\KeFlFVVOR NHL0eo5KdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N MYixPVQ3Ojl5NR?=
DU145 NGLjVI9McW6jc3WgRZN{[Xl? M3fHPFAvOSEQvF2= M3K2UlUhcA>? M2HibGROW09? NUnlRWtJUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O MlPzNVk1PjJ7N{W=
PC3 M2XZOmtqdmG|ZTDBd5NigQ>? MoPrNE4yKM7:TR?= NYDYXW0{PSCq M3v2fmROW09? NGCy[Y1KdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? MnmzNVk1PjJ7N{W=
DU145 M3z3UGtqdmG|ZTDBd5NigQ>? NVP4T2pTOC5zIN88US=> Mn;1OUBp MXrEUXNQ NVrLVZo5UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= M3O4[lE6PDZ{OUe1
Huh7 M4L3bGFvfGm4aYLhcEBCe3OjeR?= NVSzeFdROi53IN88US=> M1jMSlQh\GG7cx?= MX7EUXNQ NHXVXI5KdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2= NH\wS4IyPzN4ME[3Oi=>
C6/36 MVPBcpRqfmm{YXygRZN{[Xl? NXfkTpVMOi53IN88US=> NVnzb49JPCCmYYnz NYK0SmNlTE2VTx?= M2fqc2lvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? MVyxO|M3ODZ5Nh?=
U937 MUXGeY5kfGmxbjDBd5NigQ>? M1j5e|Eh|ryP MUGxJIg> M3jweGROW09? Mlr1VoVlfWOnczDiZZNidCCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? NWjUXYxKOTd4OESwPVk>
U937 M1XaO2Z2dmO2aX;uJGF{e2G7 NEHYNVQyKM7:TR?= NF3wR3EyKGh? NF7YOGdFVVOR NH\3ZoVT\WS3Y3XzJGxRWy2rbnT1Z4VlKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? NWHmcpJKOTd4OESwPVk>
murine mast cell NFriVZpHfW6ldHnvckBCe3OjeR?= NXKwPHdROSEQvF2= M1;4W|I1KGh? MkDmSG1UVw>? NILmN4VKdmirYnn0d{BidnSrZ3XuMYlv\HWlZXSgTWw3KHOnY4LleIlwdiCrbjDJ[2UheHKrbXXkJI1wfXOnIH3hd5Qh[2WubIOgZZQhOSC3TR?= M3LHU|E4Pjh2MEm5
BV-173 M{DjeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPwSFBiUUN3ME2wMlAxODByMEGwPUDPxE1? NULkb21TW0GQR1XS
K-562 NY\K[41OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMECwNFAxOjZ4IN88US=> MV\TRW5ITVJ?
BL-70 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfFdHI1UUN3ME2wMlAxODByMEiyNkDPxE1? MXXTRW5ITVJ?
EM-2 NYr4elZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\sb|RKSzVyPUCuNFAxODBzMEig{txO Mle4V2FPT0WU
LAMA-84 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwMECwNFA{OjFizszN M2KwcnNCVkeHUh?=
MEG-01 MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP5TWM2OD1yLkCwNFAxQThizszN M1vERnNCVkeHUh?=
EoL-1-cell M4Dqemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDGcotKSzVyPUCuNFAxODF|MTFOwG0> MnXPV2FPT0WU
CTV-1 NVnjSG5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMECwNFQxPCEQvF2= MnG0V2FPT0WU
TE-15 MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PZO2lEPTB;MD6wNFU5QSEQvF2= NF;5WJBUSU6JRWK=
NOS-1 NGXndWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDUT4JTUUN3ME2wMlAxPjF|IN88US=> MnzMV2FPT0WU
D-336MG MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFv4fm1KSzVyPUCuNFA3OyEQvF2= NXzTPFd{W0GQR1XS
LB1047-RCC NE\FdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rrN2lEPTB;MD6wNFk5QSEQvF2= MU\TRW5ITVJ?
LB996-RCC MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInvT5JKSzVyPUCuNFA6QTFizszN NIrWeYpUSU6JRWK=
SW982 Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfueXNKSzVyPUCuNFEyOTVizszN MnW4V2FPT0WU
TK10 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHCT3V[UUN3ME2wMlAyOTd2IN88US=> NGPscWhUSU6JRWK=
A704 M1rwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PEVmlEPTB;MD6wNVQ6OSEQvF2= MlG5V2FPT0WU
TE-8 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jDU2lEPTB;MD6wNVU4PiEQvF2= NF:3NFBUSU6JRWK=
DOHH-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnyxTWM2OD1yLkCxO|E6KM7:TR?= M2LRXnNCVkeHUh?=
HOP-62 MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7jTWM2OD1yLkCxPFM1KM7:TR?= NX7lV5VrW0GQR1XS
TE-12 MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLnTWM2OD1yLkCxPFYyKM7:TR?= NWnDdGlsW0GQR1XS
KGN MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{GxU2lEPTB;MD6wNVk1OiEQvF2= MV;TRW5ITVJ?
NCI-H1648 M2WxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMEKwNVEh|ryP MkHrV2FPT0WU
OS-RC-2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{L1bWlEPTB;MD6wNlA{KM7:TR?= MnrwV2FPT0WU
GB-1 MmLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnFTWM2OD1yLkCyNVU4KM7:TR?= NIDCbFlUSU6JRWK=
RXF393 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfrTWM2OD1yLkCyN|U4KM7:TR?= NGjTeHNUSU6JRWK=
LC-2-ad NHvneZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7TU5oyUUN3ME2wMlAzPTh4IN88US=> M1TsbXNCVkeHUh?=
KS-1 Moj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofrTWM2OD1yLkCyO|Mh|ryP MXjTRW5ITVJ?
ETK-1 NH\ZXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUf6RoFbUUN3ME2wMlAzQDN{IN88US=> NUfVb3JUW0GQR1XS
SW954 M1jScmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\JTWM2OD1yLkCyPVI4KM7:TR?= MWHTRW5ITVJ?
Becker MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTBwMEOwNFMh|ryP NUnHRpFIW0GQR1XS
MZ1-PC Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKwTWM2OD1yLkCzNVE6KM7:TR?= M2Du[nNCVkeHUh?=
ES6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjHNo1KSzVyPUCuNFMyQTNizszN MkH3V2FPT0WU
KURAMOCHI MnPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwMEO0PFch|ryP NHftTYRUSU6JRWK=
CGTH-W-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIH4boJKSzVyPUCuNFM2PDhizszN NWi5fYhOW0GQR1XS
VA-ES-BJ MmjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqzTWM2OD1yLkCzPVAzKM7:TR?= M4LON3NCVkeHUh?=
LXF-289 M2\JdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwMEO5OVYh|ryP NWDmPHRyW0GQR1XS
MPP-89 M{\U[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjtZ2pkUUN3ME2wMlA1ODR7IN88US=> M3rnT3NCVkeHUh?=
SW872 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLoWZR{UUN3ME2wMlA1OTZzIN88US=> NH3Ee2xUSU6JRWK=
SNB75 M3nOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMES0N|Uh|ryP NFGycYxUSU6JRWK=
PSN1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3L2cmlEPTB;MD6wOFQ4PCEQvF2= MlzzV2FPT0WU
LB831-BLC M2r3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwMES2NFkh|ryP NU\pR3JOW0GQR1XS
MFH-ino MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVraOG45UUN3ME2wMlA1PzJ2IN88US=> NV7TdpFVW0GQR1XS
TGBC24TKB NYD5SFAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnH5TWM2OD1yLkC0O|YyKM7:TR?= NFrCelNUSU6JRWK=
A388 NUX2b4pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\1TWM2OD1yLkC1NFk2KM7:TR?= NX\NWI9sW0GQR1XS
BB30-HNC M1jGbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSwTWM2OD1yLkC1OFM4KM7:TR?= MXrTRW5ITVJ?
GI-ME-N MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfMfWFDUUN3ME2wMlA3OTF6IN88US=> MVLTRW5ITVJ?
TGBC1TKB M2\ZZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS4OYlKSzVyPUCuNFYyPjRizszN MmK4V2FPT0WU
TE-10 M3nKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofFTWM2OD1yLkC2N|U4KM7:TR?= M{PvR3NCVkeHUh?=
A498 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV62R2hzUUN3ME2wMlA4Ojh2IN88US=> MU\TRW5ITVJ?
TE-11 M1;pc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK3[WVKSzVyPUCuNFc5PThizszN NHjhNWpUSU6JRWK=
BB65-RCC MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\XTWM2OD1yLkC4NlI4KM7:TR?= M171eHNCVkeHUh?=
C2BBe1 M3K2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7W[I1KSzVyPUCuNFg{ODhizszN NFTlSYNUSU6JRWK=
NCI-H747 NGnV[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3zcVNkUUN3ME2wMlA5OzZ{IN88US=> MkKzV2FPT0WU
IST-MES1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rKN2lEPTB;MD6wPFU2OiEQvF2= M4jV[HNCVkeHUh?=
KALS-1 NIrSRYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzaZ29WUUN3ME2wMlA6PDlizszN NGDlR3pUSU6JRWK=
GCIY MlXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nJe2lEPTB;MD6wPVY2PiEQvF2= NICxUItUSU6JRWK=
RL95-2 M2TwcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjVTWM2OD1yLkGwN|gh|ryP Mki2V2FPT0WU
TE-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\UN2lEPTB;MD6xNFU1KM7:TR?= NV\rPIRvW0GQR1XS
NCI-H1355 M2Xmcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjsRlBKSzVyPUCuNVExOjhizszN M17vSnNCVkeHUh?=
SW962 NHXmVnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3m4SGlEPTB;MD6xNVI6OiEQvF2= M1nFWnNCVkeHUh?=
KLE M2PCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHsfYtxUUN3ME2wMlEyOzF5IN88US=> M1\2W3NCVkeHUh?=
MC116 NWi0fldMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;TTWM2OD1yLkGxOFEh|ryP NETnT2ZUSU6JRWK=
NMC-G1 MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M321PGlEPTB;MD6xNVYxPiEQvF2= M3z3d3NCVkeHUh?=
KU812 NGTCXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMUG4PFMh|ryP M1fnSXNCVkeHUh?=
COLO-829 NHHBTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTBwMUKyNVMh|ryP NIfFRppUSU6JRWK=
NTERA-S-cl-D1 MmPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmCwTWM2OD1yLkGyNlg{KM7:TR?= NH3YT|FUSU6JRWK=
IST-MEL1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFe3TnlKSzVyPUCuNVM1PSEQvF2= NVjsNmRjW0GQR1XS
MLMA MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrjZmhKSzVyPUCuNVQxOzJizszN NV3LWIdPW0GQR1XS
LS-123 NHGz[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofJTWM2OD1yLkG0NFY1KM7:TR?= MY\TRW5ITVJ?
LB2518-MEL MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TMTmlEPTB;MD6xOFE3OiEQvF2= M4raZnNCVkeHUh?=
NB69 NFH2d3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMUS0N|Yh|ryP MXLTRW5ITVJ?
8-MG-BA Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3QTWM2OD1yLkG1OFU5KM7:TR?= NUTx[mJqW0GQR1XS
K5 NFXDfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDJTWM2OD1yLkG2OFg6KM7:TR?= NWrRZYxiW0GQR1XS
KINGS-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjvcXNKSzVyPUCuNVY3PjZizszN MmTUV2FPT0WU
SF268 MnrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDWbolKSzVyPUCuNVc1ODRizszN NYrtRWNJW0GQR1XS
PF-382 Ml;NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:y[Y9nUUN3ME2wMlE4Pjd6IN88US=> MoPaV2FPT0WU
SH-4 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfHTWM2OD1yLkG4OFE{KM7:TR?= NHTldFBUSU6JRWK=
NALM-6 MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\JZ4VKSzVyPUCuNVkzQTVizszN NVjZW3htW0GQR1XS
CP66-MEL NEDqPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzmTWM2OD1yLkG5OVMyKM7:TR?= M33lXnNCVkeHUh?=
697 Mo\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmntTWM2OD1yLkG5PVg4KM7:TR?= MVrTRW5ITVJ?
CP67-MEL MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmL4TWM2OD1yLkKwOFg5KM7:TR?= M3n0UHNCVkeHUh?=
DSH1 NUXZbHJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrrV2pKSzVyPUCuNlQxODFizszN NWDJbJl3W0GQR1XS
HCE-4 M3;RVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrDN4lKSzVyPUCuNlY1OzlizszN M4nkenNCVkeHUh?=
MZ2-MEL M2e2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPhRXZKSzVyPUCuNlg2OzdizszN MVrTRW5ITVJ?
BL-41 MkPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DvSmlEPTB;MD6yPVEzOyEQvF2= MXrTRW5ITVJ?
HUTU-80 NV3jW4dJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwM{G0NkDPxE1? MkHTV2FPT0WU
LOXIMVI NUj4RmdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPVTWM2OD1yLkOxOVA{KM7:TR?= MV7TRW5ITVJ?
no-10 NWXuTJFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OyW2lEPTB;MD6zNVk{OSEQvF2= M3HvXXNCVkeHUh?=
KARPAS-422 NXrLe|V4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPuTWM2OD1yLkOzPVk4KM7:TR?= MXzTRW5ITVJ?
SW684 NEDQZ41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTBwM{S5PEDPxE1? MkP4V2FPT0WU
SF126 Ml:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwM{W0NUDPxE1? NXLvc25HW0GQR1XS
D-263MG NHPoXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTWTWM2OD1yLkO2NlI1KM7:TR?= NHLSTWtUSU6JRWK=
OVCAR-4 M2fhSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\6UlZKSzVyPUCuN|c1OzNizszN M1;FOXNCVkeHUh?=
BB49-HNC NX7pdYh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TIOGlEPTB;MD6zPFU6QSEQvF2= NHHvRpNUSU6JRWK=
ONS-76 M{\TTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwNEK5OVEh|ryP MlLjV2FPT0WU
MZ7-mel M1HpUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfFTWM2OD1yLkS3PVEyKM7:TR?= M{D0NXNCVkeHUh?=
RCC10RGB NGC5N2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwNEmxNUDPxE1? NHLBeZlUSU6JRWK=
BOKU NIPC[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfXc2RrUUN3ME2wMlQ6OTN|IN88US=> NVz1d|h[W0GQR1XS
no-11 M1nZdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DRNGlEPTB;MD61NFIzQCEQvF2= NXLxe|BUW0GQR1XS
IST-SL2 M2fS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwNUCzNFIh|ryP NF;COnZUSU6JRWK=
RKO M32zV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwNUK5OlYh|ryP M{PV[XNCVkeHUh?=
HT-144 NUfYUmFvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4WxSGlEPTB;MD61N|YxQSEQvF2= MWPTRW5ITVJ?
NCI-H446 Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LrR2lEPTB;MD62Nlc3KM7:TR?= MUDTRW5ITVJ?
QIMR-WIL M4rIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrvfpFmUUN3ME2wMlcxPjJ7IN88US=> NU\4T|dJW0GQR1XS
MHH-PREB-1 MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLXR3RKSzVyPUCuO|Q1PjlizszN NUPqOmM5W0GQR1XS
EW-16 NWTK[HFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu0[oVqUUN3ME2wMlc3OTd6IN88US=> MnzrV2FPT0WU
EW-24 NWTVTY5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPmXmFJUUN3ME2wMlc5OTZ3IN88US=> MXTTRW5ITVJ?
LB373-MEL-D M2LiR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvGXZd4UUN3ME2wMlgzPTB6IN88US=> NIjaVXVUSU6JRWK=
TE-9 M37GO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfkRWN1UUN3ME2wMlg4PTN{IN88US=> M3zLOHNCVkeHUh?=
A3-KAW NF;HV2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jXS2lEPTB;MD65PFQ2OiEQvF2= NEW5[GJUSU6JRWK=
A101D MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jFTmlEPTB;MT6wN|A1OyEQvF2= NILVdGJUSU6JRWK=
OCUB-M M2i3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDV[5JKSzVyPUGuNFQ1OTJizszN Ml3sV2FPT0WU
ES4 NInrV4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuwVGVKSzVyPUGuNFUyPDVizszN NVq4NnVEW0GQR1XS
TE-6 NXfkTXk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrqTWM2OD1zLkKxNlI3KM7:TR?= MkXZV2FPT0WU
D-502MG M1XNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[1VZFKSzVyPUGuNlM{PzZizszN NIfUSYRUSU6JRWK=
KNS-42 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37vO2lEPTB;MT6yOFQyOiEQvF2= NHLOUlVUSU6JRWK=
SNU-C2B M3rOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fjSGlEPTB;MT6zNFU5QSEQvF2= MYDTRW5ITVJ?
NCI-H1838 M1rSOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTFwM{C3N|Mh|ryP Mn;LV2FPT0WU
NKM-1 NXPsPWE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwM{C4OVkh|ryP M2jTSXNCVkeHUh?=
GI-1 MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrETWM2OD1zLkO2NlIh|ryP MkjDV2FPT0WU
NB5 MnH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVGzTXM4UUN3ME2xMlM6QDJ5IN88US=> Mn\3V2FPT0WU
CAS-1 M4rwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjEWnlKSzVyPUGuOFA6QTJizszN M{[xTXNCVkeHUh?=
HCE-T MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUna[HIzUUN3ME2xMlU3PzF2IN88US=> NFjpe2VUSU6JRWK=
SBC-1 NHHFZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjGTWM2OD1zLkW3PVg1KM7:TR?= MYrTRW5ITVJ?
JiyoyeP-2003 NEPDVoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;UbWlEPTB;MT63N|Q3PiEQvF2= MorWV2FPT0WU
TE-5 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzafYZCUUN3ME2xMlc6OTN7IN88US=> NILBPHBUSU6JRWK=
CAN NFThRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7ufZdKSzVyPUGuPFIzPTJizszN MYLTRW5ITVJ?
SK-UT-1 M2HkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYKzfpUxUUN3ME2yMlE3Pjl|IN88US=> M3y0e3NCVkeHUh?=
JVM-2 NHmy[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\HW4Z6UUN3ME2yMlM3Ojh2IN88US=> NWjnNmRWW0GQR1XS
LB771-HNC MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJwNUe1OVEh|ryP Mlm0V2FPT0WU
NCCIT NXLBOpJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3L3RmlEPTB;Mj64OlYyPiEQvF2= Mmr0V2FPT0WU
NCI-H2126 M1ziO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlr4TWM2OD1{Lki3OVUzKM7:TR?= MorGV2FPT0WU
Calu-6 NHLrdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rhTmlEPTB;Mz6wOVc1OSEQvF2= NHvXOXVUSU6JRWK=
SK-LMS-1 MmjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPveoFIUUN3ME2zMlEyQDh4IN88US=> M13DT3NCVkeHUh?=
ARH-77 NF61c4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L5R2lEPTB;Mz60OlkyPSEQvF2= MoDyV2FPT0WU
NB17 NWq3ZXdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXvTWM2OD1|Lk[zPFQ4KM7:TR?= MWfTRW5ITVJ?
A253 MoDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TWfmlEPTB;Mz63N|I1PiEQvF2= M1vjcHNCVkeHUh?=
OPM-2 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fseGlEPTB;ND6yO|Y5PSEQvF2= MX3TRW5ITVJ?
MV-4-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrZR4JKSzVyPUSuN|Y1PTRizszN NGTK[ZpUSU6JRWK=
SR MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrzVWNuUUN3ME20MlQ6QTV2IN88US=> NIXYcVhUSU6JRWK=
KG-1 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D6e2lEPTB;ND62NFg1PSEQvF2= M3SyRnNCVkeHUh?=
OCI-AML2 M3H6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrRVWNKSzVyPUWuPFYyPTRizszN MVzTRW5ITVJ?
D-247MG MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITzW3pKSzVyPU[uNVI2OTlizszN MmnwV2FPT0WU
DJM-1 MmC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTZwNEi1OVgh|ryP NEfTdmtUSU6JRWK=
RPMI-6666 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPpNItUUUN3ME23MlI4ODZ5IN88US=> MlWwV2FPT0WU
KARPAS-45 NEHRXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDPXVdNUUN3ME23MlUyPjdzIN88US=> Ml:3V2FPT0WU
LP-1 Mn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLzTWM2OD15LkW0O|gzKM7:TR?= MV3TRW5ITVJ?
RS4-11 NFnPTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDVNFhKUUN3ME23MlY2Pzh5IN88US=> NGi5fnZUSU6JRWK=
DU-4475 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRThwMkG2OVIh|ryP NIn3SolUSU6JRWK=
MONO-MAC-6 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjJNoJOUUN3ME24MlI4ODZ4IN88US=> NFKx[ohUSU6JRWK=
NCI-SNU-16 NYHGU4ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRThwNU[xNlgh|ryP NFzad|NUSU6JRWK=
SJSA-1 NWX4VZhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Pq[2lEPTB;OD63NlgxPSEQvF2= MmPHV2FPT0WU
MMAC-SF MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HMeGlEPTB;OD63PVMxPyEQvF2= MVfTRW5ITVJ?
SK-NEP-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRThwOEmxOVUh|ryP MoDCV2FPT0WU
J-RT3-T3-5 MoPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRThwOU[1Nlkh|ryP MoLNV2FPT0WU
SKM-1 NFj1O5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XsS2lEPTB;OT6wNVc{PCEQvF2= NEfzSphUSU6JRWK=
LB2241-RCC M{n6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXsXlc5UUN3ME25MlAzODF{IN88US=> NXK5TlF{W0GQR1XS
SIG-M5 NUeyeJd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvhTWM2OD17LkCyOFk{KM7:TR?= M4DicXNCVkeHUh?=
EVSA-T M{izVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\TeoFKSzVyPUmuNlc4QTNizszN M{jnWnNCVkeHUh?=
GT3TKB MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\2R3dKSzVyPUmuN|U2PDZizszN MVPTRW5ITVJ?
NB6 NX;2UWZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHKyV4RKSzVyPUmuPVIzPTlizszN NW\OfXBqW0GQR1XS
EHEB NGTCUIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrN[lVSUUN3ME2xNE4xPjV4IN88US=> NXj5fm1WW0GQR1XS
HEL MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPaTWM2OD1zMD60O|c3KM7:TR?= MoTJV2FPT0WU
ALL-PO NET1SVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33BN2lEPTB;MUCuO|k{QCEQvF2= MYHTRW5ITVJ?
TGW M1f2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnu4TWM2OD1zMT6yPFI5KM7:TR?= MVfTRW5ITVJ?
BC-3 M33SOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\4R2lEPTB;MUKuNVE{QCEQvF2= M{W4OHNCVkeHUh?=
IA-LM MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDsUY5pUUN3ME2xNk41PDR3IN88US=> NX7XSZNuW0GQR1XS
UACC-257 NFXQdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jXOmlEPTB;MUKuPVE6QCEQvF2= NHG1VW5USU6JRWK=
KP-N-YS NG\qfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLLPWdiUUN3ME2xNk46Ojh|IN88US=> NFzWVmVUSU6JRWK=
Raji MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr6bWdbUUN3ME2xN{44PDl5IN88US=> MlrmV2FPT0WU
SF539 NYPuU2Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGxTWM2OD1zMz64OVU4KM7:TR?= M2P0fHNCVkeHUh?=
DMS-153 NGnyRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofGTWM2OD1zND6wNFI5KM7:TR?= Mm\GV2FPT0WU
L-540 NYjWb3g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjwPJZKSzVyPUG1MlA3PzJizszN Ml7kV2FPT0WU
MN-60 NIjtXYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnhTWM2OD1zNT6xPVc6KM7:TR?= M2mxVHNCVkeHUh?=
RPMI-8866 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT6TWM2OD1zNz60OFU1KM7:TR?= Mkn3V2FPT0WU
NCI-H510A NU\IXFRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXoTWM2OD1zOT6zPVc{KM7:TR?= NUjr[2NZW0GQR1XS
NB13 MmrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHNTnFyUUN3ME2xPU41QDd5IN88US=> NG\2SYpUSU6JRWK=
HAL-01 NVHTfGNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3H0N2lEPTB;MUmuO|U1OyEQvF2= NIHkVZZUSU6JRWK=
NCI-H720 MnrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HOfWlEPTB;MkCuNlc{OyEQvF2= Mlm2V2FPT0WU
REH NV3McYlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJyLk[zOVch|ryP M1\pdXNCVkeHUh?=
KNS-81-FD MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\6TWM2OD1{Mz6xOFYh|ryP MkT5V2FPT0WU
HC-1 M3H6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXLc2dKSzVyPUK0MlU2PTFizszN M1nMfHNCVkeHUh?=
NCI-H2141 NEHIRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjUNI04UUN3ME2yOE44PzV2IN88US=> MkntV2FPT0WU
MOLT-4 NILjZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXnRZZzUUN3ME2yOk43PzV|IN88US=> NI[3NolUSU6JRWK=
OMC-1 NHjnVnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHTS485UUN3ME2yO{4yPDJ{IN88US=> MVnTRW5ITVJ?
LC-1F MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTJ5LkOyOFUh|ryP NGjp[ZlUSU6JRWK=
NCI-H1304 M4HsdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;nUmlEPTB;MkiuNVYzQCEQvF2= NGjYfIlUSU6JRWK=
BC-1 MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n3N2lEPTB;MkiuOlUyKM7:TR?= NHfnfWpUSU6JRWK=
NCI-H64 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ7Lk[yOVMh|ryP NGTycmNUSU6JRWK=
MOLT-16 NXqwTmVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVftPINpUUN3ME2yPU43Ojl{IN88US=> NXP4e2RDW0GQR1XS
U-87-MG M{e4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHpTZliUUN3ME2zNE44PjZizszN M37GNXNCVkeHUh?=
GAK MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNzLkK2PFYh|ryP Ml\oV2FPT0WU
ES8 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVftOZVUUUN3ME2zNk4yOjV{IN88US=> NWXrcIZUW0GQR1XS
HCC1599 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;uNHlSUUN3ME2zNk4{OzJ3IN88US=> MkP1V2FPT0WU
EB-3 NV;l[mU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7ENo5KSzVyPUO0MlMyOTdizszN M2DpSXNCVkeHUh?=
HCC1187 NVjlTplwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fhc2lEPTB;M{WuPFA2OiEQvF2= M{Tpe3NCVkeHUh?=
SK-PN-DW M4XpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH3OnJyUUN3ME2zOk4yQTR|IN88US=> MV3TRW5ITVJ?
JVM-3 M2\FV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTN5LkKzN|gh|ryP NIC2WYFUSU6JRWK=
HCC2157 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH6U5FKSzVyPUO3Mlk6PDZizszN M13tU3NCVkeHUh?=
A4-Fuk MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvaTWM2OD1|OD6xNFA6KM7:TR?= NUfJWVliW0GQR1XS
COR-L279 MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDjfphKSzVyPUSwMlI5PTFizszN MlzzV2FPT0WU
DEL MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjoTWM2OD12MT65NFg3KM7:TR?= NIHPT5FUSU6JRWK=
NCI-H1395 NUH0NopOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTR{LkCxOlMh|ryP MVzTRW5ITVJ?
MHH-NB-11 NFXL[49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;XT2lEPTB;NEOuNFgyQCEQvF2= M1LHUXNCVkeHUh?=
NCI-H2107 NIPT[W9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPRSo5KSzVyPUSzMlQ5PDZizszN NY\zd2ZxW0GQR1XS
NEC8 NEPtTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7zZZhKSzVyPUS0MlM{PiEQvF2= MX;TRW5ITVJ?
COLO-684 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTR4LkKyOVgh|ryP M3S1ZnNCVkeHUh?=
LS-411N NVfWSolOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\pUlFKSzVyPUS4MlQ4PDhizszN NFrU[WxUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03041701 Recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2017 Phase 1|Phase 2
NCT02011945 Active not recruiting Chronic Myeloid Leukemia Bristol-Myers Squibb February 7 2014 Phase 1
NCT02389309 Recruiting Solid Tumors M.D. Anderson Cancer Center October 5 2015 Phase 1
NCT02744768 Recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto May 31 2017 Phase 2
NCT01999985 Active not recruiting Lung Cancer|Non-small Cell Lung Cancer (NSCLC) H. Lee Moffitt Cancer Center and Research Institute|Boehringer Ingelheim|Bristol-Myers Squibb December 31 2013 Phase 1
NCT01660971 Active not recruiting Metastatic Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer AJCC v6 and v7|Stage IV Pancreatic Cancer AJCC v6 and v7 National Cancer Institute (NCI) July 30 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID